A Public Interest Litigation (PIL) was filed in the Supreme Court on Wednesday, urging the establishment of a medical experts' panel to assess the risks associated with the Covishield vaccine's ...

The SII, which produced AstraZeneca’s Covid-19 vaccine under the brand name Covishield, stopped manufacturing and supply of the doses since December 2021, an SII spokesperson said. The SII ...

Covishield accounts for 90% of the 1.3 billion doses given so far in India The world's largest vaccine maker will halve the production of its Covid-19 vaccine because it has no fresh orders ...

With more than 721 million doses administered so far, Covishield is India's primary vaccine. On Tuesday, India described the rule as "discriminatory" and asked the UK to stop requiring fully ...

To assess the immunogenicity of the mRNA vaccine, Gennova will have to use Covishield — an existing vaccine — as a comparator, as the regulator has disallowed use of a placebo for the trials.

The government on Monday placed a purchase order with Serum Institute of India (SII) for 11 million doses of Oxford COVID-19 vaccine, Covishield, each costing ₹210, including the GST ...

Venugopalan Govindan, whose daughter Karunya passed away after receiving the Covishield vaccine, expressed his grief and criticised various parties for his daughter's death. He highlighted alleged ...

Covishield-maker Serum Institute applies to begin trials of its second COVID-19 vaccine Covovax: The announcement comes a day after Novovax Inc said that its Covid-19 vaccine Covovax was 89.3% ...

The SII is producing two vaccines. The first, Covishield, is one of only a few vaccines approved by the World Health Organization and is based on the COVID vaccine AstraZeneca developed.

As part of capacity-building with friendly nations in the Indian Ocean Region, India has donated two fast interceptor vessels ...

India strengthens maritime security in Mozambique through capacity-building initiatives, including gifting vessels and ...

Serum Institute of India has benefitted from sales of its "Covishield" branded vaccines during the COVID-19 pandemic, and since then, has also invested in other vaccines for malaria, dengue and ...